Drug-drug interactions (DDI) can be fatal or harmful to a patient taking multiple medications by causing up-regulation or inhibition of drug-metabolizing enzymes or altering activity of drug transporters. Understanding DDI potential of an investigational new drug before clinical trials can help bolster safety data and evaluate risk. To learn more about why DDI potential of a compound is important or to contract relevant studies, visit our Drug-Drug Interactions (DDI) informational page.
A Guide to What, Why & When to Conduct ADME Studies When drug developers are preparing their IND, drug metabolism...
Since most new drugs fail because of ADME/Tox, you can add considerable value to your compound by conducting early in...
The FDA has released a new draft guidance for industry titled “Clinical Pharmacology Considerations for the Development of Oligonucleotide Therapeutics.”...
What are drug transporters? Drug transporters are membrane-bound proteins that assist in the movement of drugs into or out of...
Over the years, we have received a lot of questions about cytochrome P450 (CYP) 2C induction studies. In February of...
Many compounds bind to or diffuse into red blood cells (RBCs), which can significantly impact clearance and cause inaccuracies in PK calculations...
Reflecting on the virtual conferences in 2021, I would like to look back at some of the highlights from the...
Over the course of 2021, we expanded access to two important and related study offerings at our US laboratory headquarters....
With over 3500 respondents, only 4% of respondents said they had never experienced any repercussions from postponing these studies...
Agility and focused growth allow drug developers to outsource expertise and benefit the industry at-large by fostering innovation. Panelists at the 2021 Annual DMDG Meeting…
Repurposing (repositioning, re-profiling, or re-tasking) a drug potentially saves years of costly testing from going to waste and potentially providing a higher chance of success.…
“Exploring alternative uses for drugs tapped for other indications, can save considerable time and money in discovery, according to an...
In preclinical development, a drug will be evaluated for potential to cause a drug-drug interaction (DDI) using in vitro experiments and then calculations that...
“Given the rapid spread of COVID-19 and its relatively high mortality, filling the gap for coronavirus-specific drugs is urgent. […]...
Drug metabolism and pharmacokinetics (DMPK) is a core discipline in drug development that considers the biotransformation of a drug compound...
Highlights from the recent webinar presented by our newest expert consultant, Dr. Pallavi Limaye In her recent webinar (now available for...
As a global Life Sciences and Healthcare company, XenoTech recognizes the seriousness of the Coronavirus Pandemic. We are constantly monitoring...
In its most recent in vitro drug interaction guidance update, the US Food and Drug Administration (FDA) emphasized harmony with the...
1. Collect high-quality data to make informed, confident go/no go decisions for moving your drug candidate forward If you need...
Beyond the need for evidence that a drug works, Food and Drug Administration (FDA) and other regulatory bodies around the...
Test systems for DMPK in vitro studies are part of the very foundation of our company. Our labs were borne of...
Dr. Ogilvie’s presentation discusses critical literature and case studies which have been published following the FDA’s 2017 guidance revision, and covered...
Why do induction studies? Induction potential is an important piece of the drug-drug interaction (DDI) component of an IND submission. Simply put, we...
While liver and intestine are important in ADME, behavior in blood is also crucial. When an orally administered drug or...
Not only can drug transporters affect the absorption and excretion of drugs, they can be involved in pharmacokinetic-based drug-drug interactions...
That is the question. . . Knowing the answer may save you time and money Good Laboratory Practices (GLP) are...
At the 2018 Marbach Castle Drug-Drug Interaction Workshop in Germany, Dr. Brian Ogilvie, Vice President of Scientific Consulting, presented a comparison...
The clinically-relevant drug-drug interaction (DDI) between the dyslipidemia drug gemfibrozil and the antidiabetic repaglinide is well-documented throughout the literature. In...
Check out the recent IQ consortium publication: Considerations from the IQ Induction Working Group in Response to Drug-Drug Interaction Guidances from...
XenoTech scientists published a paper in Drug Metabolism and Disposition evaluating Ketoconazole and its alternative clinical CYP3A4-5 inhibitors as inhibitors of drug...